Bioatla highlighted clinical program and pipeline updates at virtual r&d day

San diego, july 25, 2024 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today hosted a virtual r&d day on its novel conditionally and reversibly active antibody drug conjugate mecbotamab vedotin, targeting the receptor tyrosine kinase axl, and its antibody targeting ctla-4, evalstotug. the r&d day also featured renowned key opinion leaders, dr. edwin yau, dr. omid hamid and dr. ankit mangla.
BCAB Ratings Summary
BCAB Quant Ranking